Neolpharma, Inc.

Form 483 issued June 7, 2017 · Caguas, Puerto Rico

Inspection
May 23 – Jun 7, 2017
Observations
2
Pages
3
FEI number
3009993897

In short: On June 7, 2017, FDA issued a Form 483 with 2 observations to Neolpharma, Inc. in Caguas, Puerto Rico (FEI 3009993897) after an inspection that ran May 23 – Jun 7, 2017. The investigators were Libia M. Lugo and Rebeca Melendez. Most observations concern production and laboratory controls.

At a glance

Production and laboratory controls account for 2 of 2 observations.

Production1
Laboratory controls1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not…

  2. 02

    Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Neolpharma, Inc.?

FDA listed 2 observations on this Form 483, mostly about production and laboratory controls. The opening words of each observation are shown on this page.

Who inspected Neolpharma, Inc.?

Libia M. Lugo and Rebeca Melendez are named on this Form 483, for the inspection of May 23 – Jun 7, 2017. Each investigator has a profile showing what they cite most.

When was Neolpharma, Inc. inspected by FDA?

The inspection ran May 23 – Jun 7, 2017, and the Form 483 is dated June 7, 2017.

How do I get the full Form 483 for Neolpharma, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free